公开(公告)号：US08536160B2

公开(公告)日：2013-09-17

申请号：US12296532

申请日：2007-04-11

申请人： Alberto Cerri ,  Giorgio Fedrizzi ,  Alessandra Benicchio ,  Giuseppe Bianchi ,  Patrizia Ferrari ,  Mauro Gobbini ,  Rosamaria Micheletti ,  Marco Pozzi ,  Piero Enrico Scotti

发明人： Alberto Cerri ,  Giorgio Fedrizzi ,  Alessandra Benicchio ,  Giuseppe Bianchi ,  Patrizia Ferrari ,  Mauro Gobbini ,  Rosamaria Micheletti ,  Marco Pozzi ,  Piero Enrico Scotti

IPC分类号： A61K31/58 ,  A61P9/12 ,  C07J43/00

CPC分类号： C07J43/003

摘要： Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

摘要翻译： 式（I）化合物其中：所述基团如说明书中所定义，可用于制备用于治疗心血管疾病，特别是心力衰竭和高血压的药物。 这些化合物是Na +，K + -ATP酶的酶活性的抑制剂。 它们可用于制备用于治疗由内源性哇巴因的高血压作用引起的疾病的药物，例如常染色体显性多囊肾病（ADPKD）的肾衰竭进展，先兆子痫高血压和蛋白尿和肾衰竭进展 adducin多态性。

公开(公告)号：US20090275542A1

公开(公告)日：2009-11-05

申请号：US12296532

申请日：2007-04-11

申请人： Alberto Cerri ,  Giorgio Fedrizzi ,  Alessandra Benicchio ,  Giuseppe Bianchi ,  Patrizia Ferrari ,  Mauro Gobbini ,  Rosamaria Micheletti ,  Marco Pozzi ,  Piero Enrico Scotti

发明人： Alberto Cerri ,  Giorgio Fedrizzi ,  Alessandra Benicchio ,  Giuseppe Bianchi ,  Patrizia Ferrari ,  Mauro Gobbini ,  Rosamaria Micheletti ,  Marco Pozzi ,  Piero Enrico Scotti

IPC分类号： A61K31/58 ,  C07J43/00 ,  A61P9/04 ,  A61P9/12

CPC分类号： C07J43/003

摘要： Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

摘要翻译： 式（I）化合物其中：所述基团如说明书中所定义，可用于制备用于治疗心血管疾病，特别是心力衰竭和高血压的药物。 这些化合物是Na +，K + -ATP酶的酶活性的抑制剂。 它们可用于制备用于治疗由内源性哇巴因的高血压作用引起的疾病的药物，例如常染色体显性多囊肾病（ADPKD）的肾衰竭进展，先兆子痫高血压和蛋白尿以及肾衰竭进展 adducin多态性。